Aciphex
Small molecule
Mylan Pharmaceuticals IncAciphex is one of 12 small molecule programs targeting Laryngopharyngeal Reflux. It is currently in development.
1
Indications
5
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Laryngopharyngeal Reflux
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Zantac 150
CChattem
Approved
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Motilitone
DDong-A Pharmaceutical Co., Ltd.
Phase 3
Sodium Alginate
KKyungpook National University Hospital
Phase 3
Dexilant
TakedaPreclinical
Fosamprenavir Calcium
MMedical College of Wisconsin
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastric1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aciphex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company